Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder

The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Velez, Fulton F., Malone, Daniel C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381930/
https://www.ncbi.nlm.nih.gov/pubmed/34434535
http://dx.doi.org/10.1080/20016689.2021.1966187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381930/
https://www.ncbi.nlm.nih.gov/pubmed/34434535
http://dx.doi.org/10.1080/20016689.2021.1966187

Ejemplares similares